Melperon Aristo (Melperone Hydrochloride)

Melperon Aristo, a butyrophenone antipsychotic, acts on dopaminergic pathways to manage psychotic conditions.

• Schizophrenia: Reduces both positive symptoms such as hallucinations and delusions, and negative symptoms including social withdrawal and flattened affect, thereby improving overall functional outcome.
• Other psychotic disorders: Provides symptom control in acute psychotic episodes and maintenance therapy for conditions like schizoaffective disorder, helping to stabilize mood and thought processes.

• Melperone exerts its antipsychotic effect primarily by antagonizing dopamine D2 receptors in the mesolimbic and mesocortical pathways. This blockade diminishes dopaminergic neurotransmission that is thought to underlie psychotic symptoms. The drug also exhibits moderate affinity for serotonin 5‑HT2 receptors, contributing to its overall pharmacodynamic profile. Additionally, melperone may influence alpha‑adrenergic and histamine H1 receptors, which can affect sedation and orthostatic tolerance, though these actions are less pronounced than its dopamine antagonism.

Melperon Aristo may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Drowsiness: Feeling of sleepiness or reduced alertness.
• Dry mouth: Decreased salivation leading to oral discomfort.
• Constipation: Reduced bowel movements causing abdominal discomfort.
• Weight gain: Increase in body weight over time.

Serious or Rare Side Effects

• Extrapyramidal symptoms: Muscle rigidity, tremor, or involuntary movements.
• Neuroleptic malignant syndrome: Rare but life‑threatening reaction with fever, muscle rigidity, and autonomic instability.
• Tardive dyskinesia: Persistent involuntary facial or limb movements after prolonged use.

When prescribing Melperon Aristo, clinicians should consider several precautionary measures to ensure patient safety.

• Cardiac monitoring: Assess for QT prolongation, especially in patients with cardiac risk factors.
• Metabolic assessment: Monitor weight, glucose, and lipid levels during long‑term therapy.
• CNS depression: Caution in patients operating machinery or driving due to possible sedation.
• Elderly patients: Use lower doses and monitor for increased sensitivity to side effects.
• Drug withdrawal: Do not discontinue abruptly; taper under medical supervision to avoid rebound psychosis.
• Store at ambient temperature: Keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Melperon Aristo can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CYP2D6 inhibitors: Drugs such as fluoxetine or paroxetine may increase melperone plasma levels, raising toxicity risk.
• QT‑prolonging agents: Co‑administration with other QT‑prolonging drugs (e.g., quinidine, haloperidol) can exacerbate cardiac arrhythmia risk.

Moderate Interactions (Monitor Closely)

• CNS depressants: Alcohol, benzodiazepines, or opioids may enhance sedative effects.
• Anticholinergic drugs: May worsen dry mouth and constipation.
• Dopamine agonists: Can reduce antipsychotic efficacy, requiring dose adjustments.
• Antihypertensives: May cause additive orthostatic hypotension.